Fluorogenic Phospholipid Substrate to Detect Lysophospholipase D/Autotaxin Activity
摘要:
Lysophospholipase D (lysoPLD), also known as autotaxin (ATX), is an important source of the potent mitogen lysophosphatidic acid (LPA). Two fluorogenic substrate analogues for lysoPLD were synthesized in nine steps from (S)-PMB-glycerol. The substrates (FS-2 and FS-3) show significant increases in fluorescence when treated with recombinant ATX and have potential applications in screening for this emerging drug target.
Fluorogenic Phospholipid Substrate to Detect Lysophospholipase D/Autotaxin Activity
摘要:
Lysophospholipase D (lysoPLD), also known as autotaxin (ATX), is an important source of the potent mitogen lysophosphatidic acid (LPA). Two fluorogenic substrate analogues for lysoPLD were synthesized in nine steps from (S)-PMB-glycerol. The substrates (FS-2 and FS-3) show significant increases in fluorescence when treated with recombinant ATX and have potential applications in screening for this emerging drug target.
Compounds and methods of use thereof for assaying lysophospholipase D activity
申请人:Echelon Biosciences Incorporated
公开号:US20040171096A1
公开(公告)日:2004-09-02
Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.
[EN] COMPOUNDS AND MEHTODS OF USE THEREOF FOR ASSAYING LYSOPHOSPHOLIPASE D ACTIVITY<br/>[FR] COMPOSES ET METHODES D'UTILISATION DE CES DERNIERS POUR MESURER L'ACTIVITE LYSOPHOSPHOLIPASE D
申请人:ECHELON BIOSCIENCES INC
公开号:WO2004053459A2
公开(公告)日:2004-06-24
Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.